simultaneous use of rosuvastatin and cyclosporine has no effect on the plasma concentration of cyclosporin, but amplifies the effect of rosuvastatin.
Erythromycin increases intestinal motility, which reduces the effect of rosuvastatin .
in patients receiving vitamin dianabol steroid antagonists (eg, warfarin) is recommended to monitor international normalized ratio, since the beginning of therapy with rosuvastatin or increasing the dose of the drug can lead to an increase in INR rosuvastatin and cancellation or reduction of the dose may result in its reduction. Gemfibrozil increases the effect of rosuvastatin. The simultaneous use of antacids and rosuvastatin containing aluminum or magnesium hydroxide, results in decreased plasma rosuvastatin concentrations of about 50%. This effect is less pronounced, if antacids are used in 2 hours after taking rosuvastatin.
Concomitant use of rosuvastatin and oral contraceptives increases the AUC of ethinyl estradiol and norgestrel of 26% and 34% respectively, which should be considered when selecting oral contraceptive doses. Pharmacokinetic data for the simultaneous application of rosuvastatin and hormone replacement therapy are not available, therefore, a similar effect can not be excluded and the use of this combination.
The results showed that rosuvastatin is neither an inhibitor or inducer isoenzyme activities. Rosuvastatin is a non-core substrate for these isoenzymes. There were no clinically significant interactions with other drugs such as fluconazole, itraconazole and ketoconazole associated with metabolism by cytochrome dianabol steroidsystem.
No clinically significant interaction observed with digoxin rosuvastatin or fenofibrate, gemfibrozil, other hypolipidemic fibrates and nicotinic acid dose (at least 1 g / day) increased the risk of myopathy with concomitant use of other inhibitors reductase. Perhaps due to the fact that they can cause myopathy and when used as monotherapy.
The combined use of rosuvastatin, and ezetimibe do not lead to changes .
The protease inhibitors (virus of human immunodeficiency) with rosuvastatin may lead to significant enhancement of the effect of rosuvastatin. Pharmacokinetic study in healthy volunteers combined use of 20 mg of rosuvastatin and a combination of two HIV protease inhibitors (400 mg lopinavir / ritonavir 100 mg) resulted in approximately two-and five-fold increase Thus, in patients infected co-administration of rosuvastatin with HIV protease inhibitors is not recommended.
During treatment, especially during dose adjustment , every 2-4 weeks should monitor the lipid profile and change the dose if needed.
It is recommended that the definition of indicators of liver function before treatment and at 3 months after initiation of therapy. Admission drug dianabol steroidshould be discontinued or the dose reduced if the serum level of activity of “liver” transaminases 3 times the upper limit of normal.
In the applicationat is recommended to control pokaza¬teli renal function.
In patients with hypercholesterolemia due to hypothyroidism or nephrotic syndrome, the underlying disease therapy should be carried out prior to the start of treatment .
In patients with existing risk factors for rhabdomyolysis is necessary to consider the ratio of expected benefits and potential risks and to carry out clinical observation throughout the course of treatment.
It should inform the patient about the need for immediate reporting doctor cases of sudden appearance of muscular aches, weakness or muscle spasms, especially in combination with malaise and fever.These patients should determine. Therapy should be discontinued if dianabol steroid activity was significantly increased (more than 5 times the upper limit of normal) or if symptoms of pronounced muscle and cause discomfort daily.